<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097588</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00016288</org_study_id>
    <secondary_id>NCI-2017-00548</secondary_id>
    <secondary_id>STUDY00016288</secondary_id>
    <nct_id>NCT03097588</nct_id>
  </id_info>
  <brief_title>Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant</brief_title>
  <official_title>A Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen Prior to Hematopoietic Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinn Therapeutics (U.S.), Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well netupitant and palonosetron hydrochloride work in&#xD;
      preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM&#xD;
      conditioning regimen before stem cell transplant. Chemotherapy, such as carmustine,&#xD;
      cytarabine, etoposide, and melphalan (BEAM), makes people feel sick to their stomach and&#xD;
      causes vomiting. Netupitant and palonosetron hydrochloride may reduce the nausea and vomiting&#xD;
      caused by the BEAM treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy of netupitant and palonosetron hydrochloride (NEPA) to prevent&#xD;
      nausea and vomiting both during and after a highly emetogenic (BEAM) conditioning regimen for&#xD;
      hematopoietic stem cell transplantation (HSCT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To differentiate response to NEPA over different phases of chemotherapy-induced nausea.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and&#xD;
      palonosetron hydrochloride orally (PO) on days 1, 3, and 6.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Defined as no Emesis and no Rescue Therapy</measure>
    <time_frame>Up to 5 days post chemotherapy</time_frame>
    <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR (Acute Phase)</measure>
    <time_frame>Up to 144 hours post-study drug administration on day 1</time_frame>
    <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 144 hours (acute phase) of the study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR (Delayed Phase)</measure>
    <time_frame>From 145 hours up to 264 hours post-study drug administration on day 1</time_frame>
    <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 145 hours up to 264 hours (delayed phase) of the study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Protection (CP) Rate Defined as CR Plus no Nausea</measure>
    <time_frame>Up to 264 hours post-study drug administration on day 1</time_frame>
    <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 264 hours of the study drug administration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Emetic Episodes and Received Rescue Agents</measure>
    <time_frame>Up to 264 hours</time_frame>
    <description>The number of participants that had emetic episodes and received rescue agents (medications).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</measure>
    <time_frame>Up to 144 hours post-study drug administration on day 1</time_frame>
    <description>The number of participants that had emetic episodes and received rescue agents (medications) (acute phase: for 0 to 144 hours timeframe of study drug administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</measure>
    <time_frame>Up to 24 hours post-study drug administration on day 1</time_frame>
    <description>The number of participants that had emetic episodes and received rescue agents (medications) (for 0 to 24 hours timeframe of study drug administration)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Emetic Episodes and Received Rescue Agents (Delayed Phase)</measure>
    <time_frame>From 145 hours up to 264 hours post-study drug administration on day 1</time_frame>
    <description>The number of participants that had emetic episodes and received rescue agents (medications) during the delayed phase (for 145 hours up to 264 hours timeframe)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Levels of Nausea Per Day Assessed by Chemotherapy Induced Nausea and Vomiting Questionnaire</measure>
    <time_frame>Up to 11 days</time_frame>
    <description>The mean level of nausea per day assessed by chemotherapy induced nausea and vomiting questionnaire. The full range of nausea level score on the questionnaire was from minimum value of 0 to a maximum value of 10. 0= no nausea or vomiting, and 10= worst nausea and vomiting. Higher score means a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to First Emesis and Time to Receiving First Rescue Medication</measure>
    <time_frame>Up to 264 hours</time_frame>
    <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Receiving First Rescue Medication and First Emesis</measure>
    <time_frame>Up to 264 hours</time_frame>
    <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Supportive care (NEPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netupitant</intervention_name>
    <description>300 mg, Given PO, QD</description>
    <arm_group_label>Supportive care (NEPA)</arm_group_label>
    <other_name>CID6451149</other_name>
    <other_name>D05152</other_name>
    <other_name>RO 67-3189/000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Hydrochloride</intervention_name>
    <description>0.5 mg, Given PO, QD</description>
    <arm_group_label>Supportive care (NEPA)</arm_group_label>
    <other_name>Aloxi</other_name>
    <other_name>RS 25259-197</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Supportive care (NEPA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be undergoing autologous or allogeneic hematopoietic stem cell&#xD;
             transplant (HSCT) with the BEAM conditioning regimen prior to HSCT&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 or Karnofsky&#xD;
             Performance Score &gt;= 60%&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known hypersensitivity or other allergic reactions attributed to&#xD;
             compounds of similar biologic composition to netupitant, palonosetron, dexamethasone,&#xD;
             or other agents used in the study&#xD;
&#xD;
          -  Subjects who are receiving any other investigational agents or have received another&#xD;
             investigational drug in the last 30 days&#xD;
&#xD;
          -  Subjects who have had emesis or required antiemetics in the 48 hours prior to starting&#xD;
             the BEAM conditioning regimen; patients required to take antipsychotics, appetite&#xD;
             stimulants, or other medications with antiemetic effects will also be excluded if&#xD;
             those medications cannot be replaced by therapeutic equivalents&#xD;
&#xD;
          -  Female subjects who are pregnant, have a positive serum human chorionic gonadotrophin&#xD;
             (hCG), or are lactating and intend to breastfeed a child; pregnant women are excluded&#xD;
             from this study; breastfeeding should be discontinued if the mother is treated with&#xD;
             NEPA&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Subjects who have taken a neurokinin antagonist within 14 days prior to beginning the&#xD;
             BEAM regimen&#xD;
&#xD;
          -  Subjects who have a serum creatinine &gt; 2 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Subjects with severe renal failure or end stage renal disease (estimated GFR&#xD;
             [glomerular filtration rate] of &lt; 30 mL/min) as estimated by the Cockcroft-Gault&#xD;
             formula&#xD;
&#xD;
          -  Subjects with severe hepatic insufficiency (Child Pugh score &gt; 9)&#xD;
&#xD;
          -  Subjects who have been reported &gt; 5 alcoholic drinks daily for the last year&#xD;
&#xD;
          -  Subjects who have concurrent illness requiring systemic corticosteroid use other than&#xD;
             the planned dexamethasone during conditioning therapy&#xD;
&#xD;
          -  Subjects with gastrointestinal conditions that might result in malabsorption of the&#xD;
             study drug&#xD;
&#xD;
          -  Subjects with a history of anxiety-induced (&quot;anticipatory&quot;) nausea and vomiting&#xD;
&#xD;
          -  Subjects on strong CYP 3A4 inducers or inhibitors who are unable to have those agents&#xD;
             replaced with clinical alternatives prior to beginning the study; length of washout&#xD;
             period will be 7 days; notably, in the case of allogeneic transplant recipients&#xD;
             requiring cyclosporine or tacrolimus, no empiric dose adjustments will be required due&#xD;
             to close level monitoring and adjustments, that are standard in Oregon Health &amp;&#xD;
             Science University (OHSU) protocols&#xD;
&#xD;
          -  Subjects unable to discontinue benzodiazepines as antiemetics will not be allowed;&#xD;
             additional antiemetics will be allowed for rescue but not for prophylaxis&#xD;
&#xD;
          -  Subjects with personal or family history of QT prolongation, uncorrected electrolyte&#xD;
             abnormalities, congestive heart failure, bradyarrhythmia, conduction disturbances and&#xD;
             those taking antiarrhythmic medicinal products or other medicinal products that lead&#xD;
             to QT prolongation or electrolyte abnormalities; relevant information will be&#xD;
             collected as part of subject medical history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Bubalo</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <results_first_submitted>May 8, 2021</results_first_submitted>
  <results_first_submitted_qc>May 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2021</results_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Joseph Bubalo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03097588/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Supportive Care (NEPA)</title>
          <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO&#xD;
Palonosetron Hydrochloride: 0.5 mg, QD, Given PO&#xD;
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Supportive Care (NEPA)</title>
          <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="23" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian/other Pacific Highlander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (CR) Defined as no Emesis and no Rescue Therapy</title>
        <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy.</description>
        <time_frame>Up to 5 days post chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) Defined as no Emesis and no Rescue Therapy</title>
          <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR (Acute Phase)</title>
        <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 144 hours (acute phase) of the study drug administration.</description>
        <time_frame>Up to 144 hours post-study drug administration on day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>CR (Acute Phase)</title>
          <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 144 hours (acute phase) of the study drug administration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CR (Delayed Phase)</title>
        <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 145 hours up to 264 hours (delayed phase) of the study drug administration.</description>
        <time_frame>From 145 hours up to 264 hours post-study drug administration on day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>CR (Delayed Phase)</title>
          <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 145 hours up to 264 hours (delayed phase) of the study drug administration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Protection (CP) Rate Defined as CR Plus no Nausea</title>
        <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 264 hours of the study drug administration.</description>
        <time_frame>Up to 264 hours post-study drug administration on day 1</time_frame>
        <population>42 participants completed the study and therefore were analyzed for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Protection (CP) Rate Defined as CR Plus no Nausea</title>
          <description>Number of subjects that reached a complete response (CR), defined as having no emesis and no rescue therapy from 0 to 264 hours of the study drug administration.</description>
          <population>42 participants completed the study and therefore were analyzed for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Emetic Episodes and Received Rescue Agents</title>
        <description>The number of participants that had emetic episodes and received rescue agents (medications).</description>
        <time_frame>Up to 264 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emetic Episodes and Received Rescue Agents</title>
          <description>The number of participants that had emetic episodes and received rescue agents (medications).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants who had emetic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who were given rescue meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</title>
        <description>The number of participants that had emetic episodes and received rescue agents (medications) (acute phase: for 0 to 144 hours timeframe of study drug administration)</description>
        <time_frame>Up to 144 hours post-study drug administration on day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</title>
          <description>The number of participants that had emetic episodes and received rescue agents (medications) (acute phase: for 0 to 144 hours timeframe of study drug administration)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants who had an emetic episode in acute phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who were given rescue meds in acute phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</title>
        <description>The number of participants that had emetic episodes and received rescue agents (medications) (for 0 to 24 hours timeframe of study drug administration)</description>
        <time_frame>Up to 24 hours post-study drug administration on day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Acute Phase)</title>
          <description>The number of participants that had emetic episodes and received rescue agents (medications) (for 0 to 24 hours timeframe of study drug administration)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants that had emetic episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants that were given rescue meds-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Delayed Phase)</title>
        <description>The number of participants that had emetic episodes and received rescue agents (medications) during the delayed phase (for 145 hours up to 264 hours timeframe)</description>
        <time_frame>From 145 hours up to 264 hours post-study drug administration on day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emetic Episodes and Received Rescue Agents (Delayed Phase)</title>
          <description>The number of participants that had emetic episodes and received rescue agents (medications) during the delayed phase (for 145 hours up to 264 hours timeframe)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The number of participants that had an emetic episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The number of participants that were given rescue meds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Levels of Nausea Per Day Assessed by Chemotherapy Induced Nausea and Vomiting Questionnaire</title>
        <description>The mean level of nausea per day assessed by chemotherapy induced nausea and vomiting questionnaire. The full range of nausea level score on the questionnaire was from minimum value of 0 to a maximum value of 10. 0= no nausea or vomiting, and 10= worst nausea and vomiting. Higher score means a worse outcome.</description>
        <time_frame>Up to 11 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Levels of Nausea Per Day Assessed by Chemotherapy Induced Nausea and Vomiting Questionnaire</title>
          <description>The mean level of nausea per day assessed by chemotherapy induced nausea and vomiting questionnaire. The full range of nausea level score on the questionnaire was from minimum value of 0 to a maximum value of 10. 0= no nausea or vomiting, and 10= worst nausea and vomiting. Higher score means a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to First Emesis and Time to Receiving First Rescue Medication</title>
        <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
        <time_frame>Up to 264 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Emesis and Time to Receiving First Rescue Medication</title>
          <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median time to receiving rescue medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.4" lower_limit="130.2" upper_limit="185.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to first emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" lower_limit="168" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Receiving First Rescue Medication and First Emesis</title>
        <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
        <time_frame>Up to 264 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (NEPA)</title>
            <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Receiving First Rescue Medication and First Emesis</title>
          <description>Will be depicted via Kaplan-Meier curves showing the percentage of patients who had no emesis or rescue medication use for the acute and delayed time periods.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean time to first rescue medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="55.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean time to first emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection will begin when subject takes their first dose of study drug and continues until the subject completes the End of Study visit, up to 20 days, or until 1 month if toxicity on trial occurs, whichever comes later. Maximum duration up to 1 month.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Supportive Care (NEPA)</title>
          <description>Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.&#xD;
Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transfusion Related Acute Lung Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CD4 Lymphocytes decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lymphocyte count reduced</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Bubalo, PharmD (Oncology Clinical Pharmacy Specialist)</name_or_title>
      <organization>Department of Pharmacy Services, Oregon health &amp; Science University Hospital</organization>
      <phone>5034948007</phone>
      <email>bubaloj@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

